Safety and Efficacy Study in Acute Ischaemic Stroke

NCT00144014 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2016-06-03

No results posted yet for this study

Summary

A Phase II study to evaluate the safety and efficacy of five dose levels of study drug in acute ischaemic stroke

Conditions

Interventions

DRUG

V10153

Single acute intravenous bolus dose up to 10 mg/kg

Sponsors & Collaborators

  • Vernalis (R&D) Ltd

    lead INDUSTRY

Principal Investigators

  • Michael Hill · Foothills Hosptial

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2008-11-30
Completion
2009-03-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00144014 on ClinicalTrials.gov